Enliven Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense in USD from 2019 to 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Enliven Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2019 to 2024.
  • Enliven Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending December 31, 2024 was $5.34M, a 74.7% increase year-over-year.
  • Enliven Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending December 31, 2024 was $20.2M, a 56.2% increase year-over-year.
  • Enliven Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $20.2M, a 56.2% increase from 2023.
  • Enliven Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $12.9M, a 305% increase from 2022.
  • Enliven Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $3.19M, a 65.9% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $20.2M +$7.26M +56.2% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-13
2023 $12.9M +$9.72M +305% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-13
2022 $3.19M +$1.27M +65.9% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-14
2021 $1.92M -$307K -13.8% Jan 1, 2021 Dec 31, 2021 8-K 2023-06-23
2020 $2.23M +$1.33M +148% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-15
2019 $899K Jan 1, 2019 Dec 31, 2019 10-K 2021-03-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.